知镜 Cognispect · 医学文献与研究工作台

PRKN-Related Early-Onset Parkinson Disease

Kleinz T, Brüggemann N, Klein C.
· 2026-06-30 · PMID 20301651

文献摘要

Clinical characteristics PRKN-related early-onset Parkinson disease (PARK-PRKN) is characterized by the cardinal signs of Parkinson disease (PD): bradykinesia, resting tremor, and rigidity. The median age at onset is 31 years (range: 1-84 years). The disease is slowly progressive: a disease duration of more than 60 years has been reported. Clinical findings vary; hyperreflexia is common. Lower-limb dystonia may be a presenting sign and cognitive decline appears to be no more frequent than in the general population. Dyskinesia as a result of treatment with levodopa frequently occurs. Diagnosis/testing The diagnosis of PARK-PRKN is established in a proband with suggestive findings and biallelic pathogenic variants in PRKN identified by molecular genetic testing. Management Treatment of manifestations: Levodopa and dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors, amantadine, adenosine A2A receptor antagonists, anticholinergics; exercise as tolerated (aerobic, strength building, and integrative); physical and occupational therapy; speech and voice therapy; deep brain stimulation for those experiencing difficulty with levodopa therapy; symptomatic treatment of constipation; urology management of genitourinary manifestations; sleep aids, minimizing caffeine, good sleep hygiene, and light therapy for sleep problems; standard treatment of orthostatic hypotension; cognitive behavioral therapy, pharmacologic treatment, and/or cholinesterase inhibitor as needed for dementia. Surveillance: Neurologic examination and assessment of autonomic function and cognitive issues every six to 12 months. Agents/circumstances to avoid: Use of levodopa therapy that exceeds the dose needed for satisfactory clinical response. Neuroleptic treatment may exacerbate parkinsonism. Dopamine-blocking therapies (both typical and atypical dopamine-blocking psychiatric medications as well as dopamine blockers for gastrointestinal causes) may exacerbate parkinsonism in individuals with PARK-PRKN and should be avoided, when possible. Genetic counseling PARK-PRKN is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a PRKN pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial PRKN pathogenic variants. Once the PRKN pathogenic variants have been identified in an affected family member, heterozygote testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.

在知镜精读原文来源

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。